Fidexaban

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530131

CAS#: 183305-24-0

Description: Fidexaban is a coagulation factor and Xa inhibitor potentially for the treatment of angina pectoris.

Chemical Structure

img
Fidexaban
CAS# 183305-24-0
Instruction

Theoretical Analysis

MedKoo Cat#: 530131
Name: Fidexaban
CAS#: 183305-24-0
Chemical Formula: C25H24F2N6O5
Exact Mass: 526.18
Molecular Weight: 526.500
Elemental Analysis: C, 57.03; H, 4.59; F, 7.22; N, 15.96; O, 15.19

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: BX-807834; CI-1031; PD-200022; ZK-807834; BX807834; CI1031; PD200022; ZK807834; BX 807834; CI 1031; PD 200022; ZK 807834

IUPAC/Chemical Name: Glycine, N-(2-(5-(aminoiminomethyl)-2-hydroxyphenoxy)-6-(3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy)-3,5-difluoro-4-pyridinyl)-N-methyl-

InChi Key: NPNSVNGQJGRSNR-UHFFFAOYSA-N

InChi Code: InChI=1S/C25H24F2N6O5/c1-32-9-8-30-23(32)14-4-3-5-15(10-14)37-24-19(26)21(33(2)12-18(35)36)20(27)25(31-24)38-17-11-13(22(28)29)6-7-16(17)34/h3-7,10-11,34H,8-9,12H2,1-2H3,(H3,28,29)(H,35,36)

SMILES Code: O=C(O)CN(C1=C(F)C(OC2=CC(C(N)=N)=CC=C2O)=NC(OC3=CC=CC(C4=NCCN4C)=C3)=C1F)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 526.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Remko M, Remková A, Broer R. Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors. Molecules. 2016 Feb 4;21(2). pii: E185. doi: 10.3390/molecules21020185. PubMed PMID: 26861270.

2: Doggrell SA. Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease? Rev Recent Clin Trials. 2011 May;6(2):147-57. Review. PubMed PMID: 21241235.

3: Zafar MU, Farkouh ME, Osende J, Shimbo D, Palencia S, Crook J, Leadley R, Fuster V, Chesebro JH. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients. Thromb Haemost. 2007 Mar;97(3):487-92. PubMed PMID: 17334518.

4: Karnicki K, McBane RD 2nd, Miller RS, Leadley RJ Jr, Morser J, Owen WG, Chesebro JH. Inhibition and reversal of platelet-rich arterial thrombus in vivo: direct vs. indirect factor Xa inhibition. J Thromb Haemost. 2004 Dec;2(12):2162-9. PubMed PMID: 15613022.

5: Abendschein DR, Baum PK, Light DR, Morser J. Effect of vascular injury on inhibition of venous thrombosis with ZK-807834, a direct inhibitor of factor Xa. J Thromb Haemost. 2003 Sep;1(9):1955-8. PubMed PMID: 12941036.

6: McClanahan TB, Hicks GW, Morrison AL, Peng YW, Janiczek-Dolphin N, Mertz TE, Sullivan ME, Morser J, Juneau PL, Leadley R. The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. Eur J Pharmacol. 2001 Dec 7;432(2-3):187-94. PubMed PMID: 11740955.

7: Sinha U. ZK-807834. Berlex. Curr Opin Investig Drugs. 2002 Dec;3(12):1736-41. Review. PubMed PMID: 12528309.

8: Light DR, Guilford WJ. Discovery of the factor Xa inhibitor, ZK 807834 (CI-1031). Curr Top Med Chem. 2001 Jun;1(2):121-36. Review. PubMed PMID: 11899248.

9: Abendschein DR, Baum PK, Verhallen P, Eisenberg PR, Sullivan ME, Light DR. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs. J Pharmacol Exp Ther. 2001 Feb;296(2):567-72. PubMed PMID: 11160645.

10: Post JM, Sullivan ME, Abendschein D, Ewing J, Hinchman JW, Light DR. Human in vitro pharmacodynamic profile of the selective Factor Xa inhibitor ZK-807834 (CI-1031). Thromb Res. 2002 Feb 15;105(4):347-52. PubMed PMID: 12031830.

11: Chi L, Pen YW, Potoczak R, Gibson G, Hicks G, Mertz TE, Janiczek N, Juneau PL, Gallagher K, Leadley R. Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor. Pharmacology. 2002 Feb;64(2):76-83. PubMed PMID: 11803247.

12: Egnash LA, Ramanathan R. Comparison of heterogeneous and homogeneous radioactivity flow detectors for simultaneous profiling and LC-MS/MS characterization of metabolites. J Pharm Biomed Anal. 2002 Jan 1;27(1-2):271-84. PubMed PMID: 11682235.

13: McLean K, Schirm S, Johns A, Morser J, Light DR. FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834. Thromb Res. 2001 Aug 15;103(4):281-97. PubMed PMID: 11562339.

14: Abendschein DR, Baum PK, Martin DJ, Vergona R, Post J, Rumennik G, Sullivan ME, Eisenberg PR, Light DR. Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits. J Cardiovasc Pharmacol. 2000 May;35(5):796-805. PubMed PMID: 10813384.

15: Adler M, Davey DD, Phillips GB, Kim SH, Jancarik J, Rumennik G, Light DR, Whitlow M. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. Biochemistry. 2000 Oct 17;39(41):12534-42. PubMed PMID: 11027132.

16: Arnaiz DO, Zhao Z, Liang A, Trinh L, Witlow M, Koovakkat SK, Shaw KJ. Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors. Bioorg Med Chem Lett. 2000 May 1;10(9):957-61. PubMed PMID: 10853668.

17: Phillips GB, Buckman BO, Davey DD, Eagen KA, Guilford WJ, Hinchman J, Ho E, Koovakkat S, Liang A, Light DR, Mohan R, Ng HP, Post JM, Shaw KJ, Smith D, Subramanyam B, Sullivan ME, Trinh L, Vergona R, Walters J, White K, Whitlow M, Wu S, Xu W, Morrissey MM. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. J Med Chem. 1998 Sep 10;41(19):3557-62. PubMed PMID: 9733480.